Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.

MLA

Zalcman, Gérard, et al. “Bevacizumab for Newly Diagnosed Pleural Mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A Randomised, Controlled, Open-Label, Phase 3 Trial.” Lancet (London, England), vol. 387, no. 10026, Apr. 2016, pp. 1405–14. EBSCOhost, https://doi.org/10.1016/S0140-6736(15)01238-6.

APA

Zalcman, G., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Molinier, O., Corre, R., Monnet, I., Gounant, V., Rivière, F., Janicot, H., Gervais, R., Locher, C., Milleron, B., Tran, Q., Lebitasy, M.-P., Morin, F., Creveuil, C., … Scherpereel, A. (2016). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet (London, England), 387(10026), 1405–1414. https://doi.org/10.1016/S0140-6736(15)01238-6

Chicago

Zalcman, Gérard, Julien Mazieres, Jacques Margery, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro-Sibilot, Olivier Molinier, et al. 2016. “Bevacizumab for Newly Diagnosed Pleural Mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A Randomised, Controlled, Open-Label, Phase 3 Trial.” Lancet (London, England) 387 (10026): 1405–14. doi:10.1016/S0140-6736(15)01238-6.